301033.SZ
迈普医学
SZSE · C 制造业 · CN
CNY 55.30
−2.68%Year over year
Reported trailing growth
- Revenue
- +26.6%
- EBITDA
- —
- EBIT
- +21.4%
- EPS
- +23.4%
- Free cash flow
- -15.4%
- Operating cash flow
- -12.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +23.6%
- EBITDA
- +40.5%
- EBIT
- +45.7%
- Net income
- +46.6%
- EPS
- +46.8%
- Free cash flow
- +31.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026